多发性骨髓瘤患者血清OPG检测及临床意义

Detection of serum osteoprotegerin in patients with multiple myeloma and its clinical significance

目的：探讨OPG在多发性骨髓瘤（MM）患者血清中的表达水平及与骨病、预后的关系，初步探索其在MM骨病和预后判断中的作用。方法：采用双抗体夹心酶联免疫吸附试验（ELISA）技术分别检测28例MM患者和28例对照组的血清中OPG的水平。结果：MM患者的血清OPG水平为（222．4±114．8）pg／ml，与对照组相比明显降低（P〈0．01）。0～1个骨损组血清OPG水平为（312．4±129．6）pg／ml，而2～3个骨损组为（179．0±59．4）pg／ml，0～1个骨损组明显高于2～3个骨损组（P〈0．01）。MM患者血清OPG水平与β2-微球蛋白相关（P〈0．01），与球蛋白相关（P〈0．01），与白蛋白无关（P〉0．05），与临床分期、免疫学分型、血红蛋白、血钙未发现有相关性。结论：MM患者血清OPG水平明显低于正常对照，且其降低程度与骨损害的严重程度密切相关；同时，OPG水平与β2-微球蛋白呈负相关，提示血清OPG水平可能对MM的预后具有重要意义。

Objective：To investigate the serum osteoprotegerin （OPG） levels in patients with multiple myeloma and the association with bone disease. Method： The levels of serum OPG were detected in both 28 patients with multiple myeloma and 28 controls using ELISA. Result.. OPG levels were lower in the patients with multiple myeloma [（222.4±114.8） pg/ml] than those of the controls. OPG levels in patients with 0-1 and 2-3 bone lesions were （312.4 ± 129.6） pg/ml and （179.0 ± 59.4） pg/ml, respectively. This difference was statistically significant （ P 〈0.01）. OPG levels were not associated with Albumin levels, stage immunologic type, hemoglobin or Calcium levels, but with β2 microglobulin and globulin levels （ P 〈0. 01）. Conclusion：Serum OPG levels were reduced in patients with multiple myeloma and were associated with skeletal destruction. OPG may be used as prognosis factor for patients with multiple myeloma.